论文部分内容阅读
目的探讨益气解毒方联合同期放化疗对局部晚期鼻咽癌患者T淋巴细胞亚群及生存率的影响。方法将54例局部晚期鼻咽癌患者随机分为联合组和对照组各27例,2组均采用同期放化疗治疗,联合组加用益气解毒方辅助治疗,观察2组T淋巴细胞亚群变化及生存率。结果 2组治疗前CD3+、CD4+、CD8+、CD4+/CD8+比较差异无统计学意义(P均<0.05),治疗后3个月均较治疗前有所提高(P均<0.05),但联合组各指标均显著高于对照组(P均<0.05)。联合组毒副反应发生率明显低于对照组(P<0.05)。联合组2年、3年生存率显著高于对照组(P均<0.05),2组6个月及1年生存率比较差异无统计学意义(P均>0.05)。结论益气解毒方联合同期放化疗可显著提高局部晚期鼻咽癌患者的免疫功能和生存率,减轻放化疗毒副反应,是一种安全可行的联合治疗方案。
Objective To investigate the effect of Yiqi Jiedu Decoction combined with concurrent chemoradiotherapy on T lymphocyte subsets and survival rate in patients with locally advanced nasopharyngeal carcinoma. Methods Totally 54 patients with locally advanced nasopharyngeal carcinoma were randomly divided into two groups: 27 cases in combination group and control group. Both groups received concurrent chemoradiotherapy and chemotherapy. Adjuvant therapy with Yiqi Jiedu decoction was given in combination group. The changes of T lymphocyte subsets And survival rate. Results There was no significant difference in the levels of CD3 +, CD4 +, CD8 + and CD4 + / CD8 between the two groups before treatment (all P <0.05), and at 3 months after treatment than before treatment (all P <0.05) Indicators were significantly higher than the control group (P all <0.05). The incidence of side effects in combination group was significantly lower than that in control group (P <0.05). The 2-year and 3-year survival rates in the combined group were significantly higher than those in the control group (P <0.05). There was no significant difference in the 6-month and 1-year survival rates between the two groups (P> 0.05). Conclusions Yiqi Jiedu Decoction combined with concurrent chemoradiotherapy can significantly improve the immune function and survival rate of patients with locally advanced nasopharyngeal carcinoma and reduce the side effects of radiotherapy and chemotherapy. It is a safe and feasible combination regimen.